142 related articles for article (PubMed ID: 33741780)
1. Thromboembolic disease in hypercortisolism.
Capatina C; Fleseriu M
Curr Opin Endocrinol Diabetes Obes; 2021 Jun; 28(3):330-336. PubMed ID: 33741780
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects of glucocorticoids: coagulopathy.
Coelho MC; Santos CV; Vieira Neto L; Gadelha MR
Eur J Endocrinol; 2015 Oct; 173(4):M11-21. PubMed ID: 25971647
[TBL] [Abstract][Full Text] [Related]
3. Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment.
van der Pas R; Leebeek FW; Hofland LJ; de Herder WW; Feelders RA
Clin Endocrinol (Oxf); 2013 Apr; 78(4):481-8. PubMed ID: 23134530
[TBL] [Abstract][Full Text] [Related]
4. Hypercoagulability in Cushing's syndrome: From arterial to venous disease.
St-Jean M; Lim DST; Langlois F
Best Pract Res Clin Endocrinol Metab; 2021 Mar; 35(2):101496. PubMed ID: 33795197
[TBL] [Abstract][Full Text] [Related]
5. Hypercoagulability in Cushing's syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols.
Feelders RA; Nieman LK
Pituitary; 2022 Oct; 25(5):746-749. PubMed ID: 35881275
[TBL] [Abstract][Full Text] [Related]
6. Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).
van Haalen FM; Kaya M; Pelsma ICM; Dekkers OM; Biermasz NR; Cannegieter SC; Huisman MV; van Vlijmen BJM; Feelders RA; Klok FA; Pereira AM;
Orphanet J Rare Dis; 2022 May; 17(1):178. PubMed ID: 35505430
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.
Boscaro M; Sonino N; Scarda A; Barzon L; Fallo F; Sartori MT; Patrassi GM; Girolami A
J Clin Endocrinol Metab; 2002 Aug; 87(8):3662-6. PubMed ID: 12161492
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of vascular complications in Cushing's syndrome.
Miljic P; Miljic D; Cain JW; Korbonits M; Popovic V
Hormones (Athens); 2012; 11(1):21-30. PubMed ID: 22450342
[TBL] [Abstract][Full Text] [Related]
9. MANAGEMENT OF ENDOCRINE DISEASE: Cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing's syndrome: a practical approach.
Varlamov EV; Langlois F; Vila G; Fleseriu M
Eur J Endocrinol; 2021 Apr; 184(5):R207-R224. PubMed ID: 33539319
[TBL] [Abstract][Full Text] [Related]
10. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery.
Manetti L; Bogazzi F; Giovannetti C; Raffaelli V; Genovesi M; Pellegrini G; Ruocco L; Iannelli A; Martino E
Eur J Endocrinol; 2010 Nov; 163(5):783-91. PubMed ID: 20696792
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile.
Koutroumpi S; Daidone V; Sartori MT; Cattini MG; Albiger NM; Occhi G; Ferasin S; Frigo A; Mantero F; Casonato A; Scaroni C
Pituitary; 2013 Jun; 16(2):175-81. PubMed ID: 22585010
[TBL] [Abstract][Full Text] [Related]
12. Coagulopathy in Cushing's syndrome.
Trementino L; Arnaldi G; Appolloni G; Daidone V; Scaroni C; Casonato A; Boscaro M
Neuroendocrinology; 2010; 92 Suppl 1():55-9. PubMed ID: 20829619
[TBL] [Abstract][Full Text] [Related]
13. Clinical consequences of Cushing's syndrome.
Valassi E; Crespo I; Santos A; Webb SM
Pituitary; 2012 Sep; 15(3):319-29. PubMed ID: 22527617
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess.
Pivonello R; De Martino MC; Iacuaniello D; Simeoli C; Muscogiuri G; Carlomagno F; De Leo M; Cozzolino A; Colao A
Front Horm Res; 2016; 46():54-65. PubMed ID: 27212264
[TBL] [Abstract][Full Text] [Related]
15. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer.
Carrier M; Khorana AA; Moretto P; Le Gal G; Karp R; Zwicker JI
Am J Med; 2014 Jan; 127(1):82-6.e1. PubMed ID: 24384102
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular disease in Cushing's syndrome: heart versus vasculature.
De Leo M; Pivonello R; Auriemma RS; Cozzolino A; Vitale P; Simeoli C; De Martino MC; Lombardi G; Colao A
Neuroendocrinology; 2010; 92 Suppl 1():50-4. PubMed ID: 20829618
[TBL] [Abstract][Full Text] [Related]
17. Markers of atherosclerosis in patients with Cushing's syndrome: a meta-analysis of literature studies.
Lupoli R; Ambrosino P; Tortora A; Barba L; Lupoli GA; Di Minno MN
Ann Med; 2017 May; 49(3):206-216. PubMed ID: 27763781
[TBL] [Abstract][Full Text] [Related]
18. Hypercoagulability and Risk of Venous Thromboembolic Events in Endogenous Cushing's Syndrome: A Systematic Meta-Analysis.
Wagner J; Langlois F; Lim DST; McCartney S; Fleseriu M
Front Endocrinol (Lausanne); 2018; 9():805. PubMed ID: 30745894
[No Abstract] [Full Text] [Related]
19. A venous thromboembolism risk assessment model for patients with Cushing's syndrome.
Zilio M; Mazzai L; Sartori MT; Barbot M; Ceccato F; Daidone V; Casonato A; Saggiorato G; Noventa F; Trementino L; Prandoni P; Boscaro M; Arnaldi G; Scaroni C
Endocrine; 2016 May; 52(2):322-32. PubMed ID: 26113424
[TBL] [Abstract][Full Text] [Related]
20. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study.
Dekkers OM; Horváth-Puhó E; Jørgensen JO; Cannegieter SC; Ehrenstein V; Vandenbroucke JP; Pereira AM; Sørensen HT
J Clin Endocrinol Metab; 2013 Jun; 98(6):2277-84. PubMed ID: 23533241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
